Goldman Sachs’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q3 | – | Sell |
-56
| Closed | -$2K | – | 5832 |
|
|
2018
Q2 | $2K | Sell |
56
-977
| -95% | -$44.8K | ﹤0.01% | 5610 |
|
|
2018
Q1 | $67K | Sell |
1,033
-745
| -42% | -$52.8K | ﹤0.01% | 5394 |
|
|
2017
Q4 | $130K | Sell |
1,778
-18,044
| -91% | -$1.49M | ﹤0.01% | 5646 |
|
|
2017
Q3 | $1.82M | Buy |
19,822
+14,944
| +306% | +$1.15M | ﹤0.01% | 4085 |
|
|
2017
Q2 | $323K | Buy |
4,878
+245
| +5% | +$30.3K | ﹤0.01% | 5444 |
|
|
2017
Q1 | $1M | Buy |
4,633
+2,800
| +153% | +$400K | ﹤0.01% | 4372 |
|
|
2016
Q4 | $170K | Sell |
1,833
-34
| -2% | -$3.83K | ﹤0.01% | 5877 |
|
|
2016
Q3 | $252K | Sell |
1,867
-989
| -35% | -$98.2K | ﹤0.01% | 5616 |
|
|
2016
Q2 | $289K | Sell |
2,856
-4,088
| -59% | -$507K | ﹤0.01% | 5362 |
|
|
2016
Q1 | $1.14M | Sell |
6,944
-212
| -3% | -$43K | ﹤0.01% | 3978 |
|
|
2015
Q4 | $2.34M | Buy |
7,156
+178
| +3% | +$57.9K | ﹤0.01% | 3486 |
|
|
2015
Q3 | $2.25M | Sell |
6,978
-1,044
| -13% | -$459K | ﹤0.01% | 3674 |
|
|
2015
Q2 | $3.2M | Buy |
8,022
+1,155
| +17% | +$491K | ﹤0.01% | 3371 |
|
|
2015
Q1 | $3.38M | Sell |
6,867
-2,733
| -28% | -$1.06M | ﹤0.01% | 3279 |
|
|
2014
Q4 | $3.43M | Buy |
9,600
+1,533
| +19% | +$456K | ﹤0.01% | 3329 |
|
|
2014
Q3 | $1.55M | Buy |
8,067
+6,445
| +397% | +$1.42M | ﹤0.01% | 4170 |
|
|
2014
Q2 | $388K | Sell |
1,622
-7,800
| -83% | -$1.59M | ﹤0.01% | 5548 |
|
|
2014
Q1 | $2.41M | Sell |
9,422
-78
| -0.8% | -$23.8K | ﹤0.01% | 3799 |
|
|
2013
Q4 | $1.88M | Sell |
9,500
-2,844
| -23% | -$506K | ﹤0.01% | 4130 |
|
|
2013
Q3 | $2.09M | Buy |
12,344
+2,944
| +31% | +$474K | ﹤0.01% | 3876 |
|
|
2013
Q2 | $1.67M | Buy |
+9,400
| New | +$1.33M | ﹤0.01% | 3893 |
|
Goldman Sachs's LUMO Position: Q4 2024 in Review
Goldman Sachs sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2024, closing a stake of 362,198 shares — an estimated $1.4M sold.
Goldman Sachs first reported a position in LUMO in Q2 2013 and held it in 37 quarters. The position peaked at $5.44M in Q1 2017. 0 funds tracked by Wall St. Rank hold LUMO as of Q4 2024.
- Goldman Sachs reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Goldman Sachs sold 362,198 Lumos Pharma, Inc. Common Stock shares in Q4 2024, an estimated $1.4M.
- Goldman Sachs first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 37 quarters.
- Goldman Sachs's Lumos Pharma, Inc. Common Stock position peaked at $5.44M in Q1 2017.
- 0 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2024.
Based on Goldman Sachs's 13F filing for Q4 2024, filed 11 Feb 2025.